** Shares of medical device maker AngioDynamics rise 12.6% to $7.88 premarket
** ANGO says the U.S. FDA has cleared its medical device to treat prostate cancer
** The device, called NanoKnife System, uses electrical pulses to destroy cancer cells by creating tiny holes in their membranes
** Prostate cancer affects 1.5 mln men annually worldwide - ANGO
** As of last close, stock has fallen 10.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments